The TAM receptors Tyro3, Axl and Mertk are receptor tyrosine kinases that dampen host innate immune responses following engagement with their ligands Gas6 and Protein S, which recognize phosphatidylserine on apoptotic cells. In a form of apoptotic mimicry, many enveloped viruses display phosphatidylserine on the outer leaflet of their membranes, enabling TAM receptor activation and downregulation of antiviral responses. Accordingly, we hypothesized that a deficiency of TAM receptors would enhance antiviral responses and protect against viral infection. Unexpectedly, mice lacking Mertk and/or Axl, but not Tyro3, exhibited greater vulnerability to infection with neuroinvasive West Nile and La Crosse encephalitis viruses. This phenotype was associated with increased blood-brain barrier permeability, which enhanced virus entry into and infection of the brain. Activation of Mertk synergized with interferon-b to tighten cell junctions and prevent virus transit across brain microvascular endothelial cells. Because TAM receptors restrict pathogenesis of neuroinvasive viruses, these findings have implications for TAM antagonists that are currently in clinical development. npg
The TAM receptors Tyro3, Axl, and Mertk have pleiotropic functions in cancer metastasis, angiogenesis, thrombus stabilization and innate immune regulation 1, 2 . Axl and/or Mertk are expressed on cells that are involved in immune control and trafficking, including macrophages, dendritic cells (DCs), platelets and endothelial cells 1 . In comparison, Tyro3 expression is prominent on central nervous system (CNS) neurons 3 . TAM receptors signal upon recognition of their phosphatidylserine-bound ligands, Gas6 and Protein S (ref. 4 ). The consequences of TAM signaling depend on cell type. For example, TAM receptors are important for NK cell development 5 , and their inhibition may license NK cells to reject metastatic tumors 6 . Axl and Mertk signaling in endothelial cells modulate angiogenesis [7] [8] [9] , whereas their signaling in platelets promotes thrombus stabilization 10 . In DCs, activation of Axl downregulates production and signaling of pro-inflammatory cytokines by interacting physically with the R1 subunit of the type I interferon (IFN) receptor (Ifnar1) to promote expression of the negative regulators Socs1 and Socs3 (ref. 11) . The TAM receptors also have essential roles in clearance of apoptotic cells by macrophages, retinal pigment epithelial cells and other professional phagocytes [12] [13] [14] . The TAM ligands Gas6 and Protein S physically bridge a TAM receptor expressed on the surface of a phagocyte to phosphatidylserine expressed on the surface of the apoptotic cell.
TAM receptors are therapeutic targets in cancer because of their effects on tumor angiogenesis, NK cell licensing, tumor cell survival, metastasis and immune suppression in tumor-associated macrophages [6] [7] [8] [9] . Several antagonists and blocking antibodies are under evaluation in clinical trials 15, 16 . TAM receptor agonists also may prove useful in the treatment of autoimmunity because of their ability to downregulate cytokine production 17 . Less is known about the net effect of TAM receptor blockade during viral infection. In a form of apoptotic mimicry, many enveloped viruses incorporate phosphatidylserine into their virion membranes 18, 19 and bind Gas6 and Protein S to facilitate recognition by TAM receptors and activation of signals that dampen antiviral responses 19 . Studies with influenza and respiratory syncytial viruses suggest that Axl blockade by antibodies protects against infection and disease pathogenesis 20 . However, an antiviral phenotype after TAM inhibition may not be universal, as herpes simplex virus (HSV) infection was more severe in Axl −/− mice 21 .
We hypothesized that deletion of TAM receptors might restrict West Nile virus (WNV) infection and protect against pathogenesis for two reasons: cell culture studies indicated that TAM receptors can augment flavivirus entry 18 and create a more permissive innate immune environment for replication 19 , and WNV causes substantial morbidity in humans after it crosses the blood-brain barrier (BBB) and replicates within neurons. Type I IFN signaling strengthens the BBB during viral infection by tightening the junctions between brain microvascular endothelial cells (BMECs) 22 . Because TAM receptors can negatively regulate type I IFN signaling 11, 19 , deletion of TAM receptors could enhance both IFN signaling and BBB integrity. Unexpectedly, we observed that Axl −/− , Mertk −/− and Axl −/− Mertk −/− but not Tyro3 −/− mice were more vulnerable to WNV infection. This phenotype was associated with markedly impaired BBB integrity during infection. Our results establish a preferential role for Mertk in protecting against neuroinvasive viruses, which occurs, at least in part, through its ability to sustain the BBB during infection.
RESULTS
Axl and Mertk but not Tyro3 are required for control of WNV infection in vivo To evaluate the role of TAM receptors in WNV infection, we infected wild-type (WT), Tyro3 −/− , Axl −/− , Mertk −/− and Axl −/− Mertk −/− C57BL/6 mice with WNV (New York 2000 strain) by subcutaneous inoculation (Fig. 1a) . Unexpectedly, Axl −/− , Mertk −/− and Axl −/− Mertk −/− mice, but not Tyro3 −/− mice, were more vulnerable to WNV infection than WT mice, with ~80% mortality in Axl −/− or Mertk −/− mice (P < 0.0005) and ~95% mortality in Axl −/− Mertk −/− mice (P < 0.0005).
We found that an absence of TAM receptors had a relatively minor effect on viral burden in peripheral organs, with increased viremia and viral loads observed only at 2 d post infection (d.p.i.) in the serum (26-fold, P < 0.05) and 4 d.p.i. in the spleen (33-fold, P < 0.05), respectively, in the Axl −/− Mertk −/− mice (Fig. 1b,c) . No significant differences in viral burden were observed in the sera, spleens or kidneys of Axl −/− or Mertk −/− mice, as compared to WT mice ( Fig. 1b-d) .
Higher levels of WNV infection were apparent in the CNS of Axl −/− , Mertk −/− and Axl −/− Mertk −/− mice, as compared to WT controls. At 4 d.p.i., WNV was detected in CNS tissues of TAM receptor-deficient mice: 2 of 9 Axl −/− , 2 of 10 Mertk −/− and 3 of 10 Axl −/− Mertk −/− mice had brain homogenates that were positive for infectious WNV, as compared to those in 0 of 10 WT mice ( Fig. 1e) . Analogously, at 6 d.p.i., 5 of 9 Axl −/− , 4 of 8 Mertk −/− and 4 of 9 Axl −/− Mertk −/− mice had detectable WNV in the spinal cord, as compared to 0 of 10 WT mice ( Fig. 1f ). Viral titers also were increased at 8 d.p.i. in the brains (29-to 72-fold increase, P < 0.05) and spinal cords (7-to 135-fold increase, P < 0.05) of Axl −/− , Mertk −/− and Axl −/− Mertk −/− mice.
Higher levels of CNS infection in the TAM receptor-knockout mice suggest that Axl or Mertk restrict viral replication preferentially in target cells of the CNS. To test this hypothesis, we inoculated WNV intracranially in Axl −/− , Mertk −/− or Tyro3 −/− mice. To ensure detection of small differences that might be missed by whole-brain analysis, viral burdens in the cerebral cortex, subcortex, brain stem and cerebellum were measured at 3, 5 and 6 d.p.i. Later time points could not be studied as all mice succumbed to WNV infection by day 7 after intracranial inoculation. No difference in viral burden in the CNS of Axl −/− , Mertk −/− or Tyro3 −/− mice was observed after intracranial inoculation, as compared to that in WT mice ( Fig. 1g-i , P > 0.9). These data suggest that TAM receptors do not restrict WNV replication directly in the CNS.
Effects of TAM receptors on antiviral adaptive immune responses
To assess whether a part of the observed CNS virological phenotype could be attributed to defects in adaptive immunity, we measured anti-WNV IgM and IgG levels at 4 and 8 d.p.i. in WT and Axl −/− Mertk −/− mice (Supplementary Fig. 1a-c) . Axl −/− Mertk −/− mice had slightly greater anti-WNV IgG titers (2.5-fold, P < 0.005) and slightly lower WNV-neutralizing antibody titers at 8 d.p.i. (0.4-fold, P < 0.005). These small differences are probably not sufficient to explain the prominent lethality phenotype that was observed in Axl −/− Mertk −/− mice after WNV infection.
Axl has been proposed to modulate CD8 + T cell responses by DC efferocytosis and antigen cross-presentation 21 . To test whether npg Axl and Mertk affected T cell responses during WNV infection, we measured the levels and antigen specificity of CD8 + T cells from the spleens of WNV-infected WT, Axl −/− , Mertk −/− and Axl −/− Mertk −/− mice ( Supplementary Fig. 1d-n) . Although we detected similar numbers and percentages of CD4 + and CD8 + T cells in the spleens of WT, Axl −/− , Mertk −/− and Axl −/− Mertk −/− mice at 8 d.p.i., we observed fewer WNV tetramer-positive CD8 + T cells in Axl −/− mice as compared to WT mice ( Supplementary Fig. 1d-f ). After ex vivo peptide restimulation of splenocytes, we observed a lower percentage and number of WNV-specific CD8 + T cells that expressed IFN-γ in Axl −/− but not Mertk −/− CD8 + T cells ( Supplementary Fig. 1k ,l; P < 0.05). There also were fewer WNV-specific CD8 + T cells that expressed IFN-γ or tumor necrosis factor (TNF)-α from Axl −/− Mertk −/− mice ( Supplementary  Fig. 1m ,n; P < 0.05). These data suggest that Axl is required for optimal priming of a CD8 + T cell response during WNV infection. We next assessed leukocyte responses within the brain at 8 d.p.i. We observed greater numbers of leukocytes and antigen-specific CD8 + T cells in the brains of Mertk −/− and Axl −/− Mertk −/− mice than in those of WT controls ( Supplementary Fig. 2a -g; P < 0.05). However, there was no statistically significant difference in the number of CD11b + CD45 hi macrophages or CD11b + CD45 lo microglia, which are cells that contribute to clearance of WNV in the brain ( Supplementary Fig. 2h ,i). Greater numbers of infiltrating immune cells probably result from the higher viral burden in the CNS, enhanced BBB permeability or both.
BBB integrity during WNV infection requires Axl and Mertk but not Tyro3
Because we observed early accumulation of WNV in the brains of Axl −/− , Mertk −/− and Axl −/− Mertk −/− mice, we assessed whether these mice had altered BBB permeability that could impact virus entry into the CNS. We injected sodium fluorescein (molecular weight (MW) 376 Da) intraperitoneally into naive and WNV-infected WT, Tyro3 −/− , Axl −/− , Mertk −/− and Axl −/− Mertk −/− mice and measured extravasation into the brain 45 min later ( Fig. 2a) . Even in the absence of infection, naive Axl −/− Mertk −/− mice had slightly greater BBB permeability; in comparison, no statistically significant differences were observed in naive Tyro3 −/− , Axl −/− or Mertk −/− mice, although there was a trend toward enhanced BBB permeability in naive, uninfected Mertk −/− mice as compared to WT mice ( Fig. 2a ). WNV infection resulted in increased sodium fluorescein extravasation into the CNS at 4 d.p.i. (Fig. 2a) , as reported previously 22 . BBB permeability was greater in WNV-infected Axl −/− , Mertk −/− and Axl −/− Mertk −/− but not in Tyro3 −/− mice, as compared to WT mice at this time point, with Mertk −/− and Axl −/− Mertk −/− mice exhibiting the most pronounced phenotypes ( Fig. 2a) . These results suggest that Axl and Mertk are required to maintain BBB integrity during infection and prevent early virus invasion into the CNS, with Mertk having the most prominent effect.
As an independent measure of BBB permeability, we used confocal microscopy to assess leakage of endogenous IgG (MW 150,000 Da) into the brain parenchyma following WNV infection. Although minimal IgG was detected in the brains of uninfected mice corresponding to all of the genotypes (data not shown), IgG accumulation became apparent at 4 d.p.i., with Axl −/− Mertk −/− mice exhibiting greater leakage than WT mice ( Fig. 2b) . Thus, in the context of WNV infection, the BBB of Axl −/− Mertk −/− mice was more permeable to small molecules and larger proteins.
TAM antagonist disrupts BBB integrity and accelerates WNV infection in the brain
To corroborate the phenotypes observed with TAM receptor-knockout mice, we treated WT mice with BMS-777607, a small-molecule inhibitor of c-Met, Ron, Flt-3 and TAM receptor signaling (Clinicaltrials.gov ID: NCT00605618), at a dose of 40 mg per kg body weight (mg/kg) by oral gavage beginning 1 d before WNV infection and continuing until 4 d.p.i. BMS-777607 treatment resulted in enhanced lethality of WT mice after WNV infection ( Supplementary Fig. 3a ; P < 0.05) with virus present in the brain at 4 d.p.i. in 3 of 6 drug-treated mice, as compared to 0 of 6 control mice ( Supplementary Fig. 3b ). BMS-777607 treatment increased BBB permeability in WT mice at 4 d.p.i. but not in Axl −/− Mertk −/− mice at 4 d.p.i. (Supplementary Fig. 3c ; P < 0.05) or in drug-treated uninfected animals ( Supplementary Fig. 3d ).
TAM receptor-knockout mice are vulnerable to La Crosse virus infection
We hypothesized that Mertk −/− mice also might be vulnerable to other viruses that enter the brain through a hematogenous route. npg La Crosse virus (LACV) is a neurotropic orthobunyavirus that causes meningoencephalitis, predominantly in children 23 . We observed enhanced mortality in Axl −/− and Mertk −/− mice infected with LACV, as compared to WT mice ( Fig. 3a ; 50% versus 9%, P < 0.05). Mertk −/− mice had increased BBB permeability at 4 d.p.i., whereas LACVinfected Axl −/− mice did not ( Fig. 3b ). We also found higher levels of viral RNA in the brains of Mertk −/− but not Axl −/− mice at 8 d.p.i. (Fig. 3c ) with LACV.
Cytokine and chemokine levels in sera of WNV-infected mice Elevated levels of some pro-inflammatory cytokines (such as TNF-α) open the BBB 24 , whereas others (such as type I IFN) close the barrier 22 . Because TAM receptors negatively regulate cytokine production, we measured the levels of TNF-α and type I IFN in the sera of naive and WNV-infected mice (Supplementary Fig. 4 ). Prior to infection, Axl −/− , Mertk −/− and Axl −/− Mertk −/− mice had higher levels of IL-12(p40) than WT mice, although the levels of other pro-inflammatory cytokines were similar to those in WT animals. At 4 d.p.i., levels of TNF-α, IL-1β, IL-6, IL-12(p40), RANTES and KC were slightly higher (~2-to 3-fold; P < 0.05) in the sera of Axl −/− , Mertk −/− and Axl −/− Mertk −/− mice as compared to WT mice ( Supplementary Fig. 4a-g) ; serum type I IFN levels were also slightly higher in Axl −/− and Axl −/− Mertk −/− mice at 4 d.p.i. (1.3-to 1.5-fold; P < 0.05) but not in Mertk −/− mice (P > 0.9) ( Supplementary Fig. 4h ).
We also assessed cytokine levels in the brains of Axl −/− , Mertk −/− and Axl −/− Mertk −/− mice that were inoculated with WNV via intracranial injection (Supplementary Fig. 4i ) to measure cytokine expression levels in the context of equivalent WNV burden in WT and TAM receptor-deficient mice ( Fig. 1g-i) . We found no difference in mRNA expression of TNF-α, IL-1β, IL-6, TGF-β1 and TGF-β3 among any of the genotypes. Consistent with this finding, antibody blockade of TNF-α in vivo did not change the BBB permeability defect observed in Axl −/− Mertk −/− mice on infection with WNV (data not shown). Thus, the net effect of the differences in the levels of pro-inflammatory cytokines on BBB permeability in TAM receptor-deficient mice remains unclear.
Axl and Mertk signaling improves BBB integrity in vitro TAM receptors are present on the surface of mouse BMECs in vivo and in vitro, with higher expression of Mertk as compared to Axl 25, 26 (Supplementary Fig. 5a-c) . To explore whether TAM receptor signaling modulates endothelial barrier integrity and WNV transit, we used an in vitro model of the BBB 22 . Primary mouse BMECs were cultured in the upper chamber of a Transwell plate, and primary astrocytes were cultured in the lower chamber. Transendothelial electrical resistance (TEER) across the BMEC monolayer measures barrier integrity, with higher resistance indicating a tighter barrier. TEER was lower across Axl −/− Mertk −/− BMECs ( Fig. 4a ; P < 0.05) at baseline. In response to WNV infection, and as expected, WT and Axl −/− Mertk −/− BMEC barriers exhibited increased TEER, as compared with mock-infected barriers; however, Axl −/− Mertk −/− BMEC barriers failed to tighten as much as WT BMEC barriers ( Fig. 4a,b ; 0.85-fold, P < 0.0001). We observed no difference in viability between WT and Axl −/− Mertk −/− BMECs (data not shown).
We next evaluated whether changes in the TEER of Axl −/− Mertk −/− BMECs affected transit of WNV across the endothelial barrier. We added WNV to the upper chamber and measured virus that had crossed the BMEC barrier into the lower chamber after 6 h; this time point precedes de novo spread of WNV infection 27 . Consistent with lower TEER, Axl −/− Mertk −/− BMECs had higher amounts (ninefold, P < 0.0001) of WNV crossing into the lower chamber than WT cells ( Fig. 4c) . Higher levels of WNV in the lower chamber could result from decreased binding of WNV to BMECs in the absence of Axl and Mertk, as these receptors are engaged by WNV at the plasma membrane 18 ; however, we found slightly higher amounts of WNV associated with BMECs lacking Axl and Mertk expression at 6 h after infection ( Fig. 4d) . Thus, Axl and Mertk are not required for binding of WNV to BMECs, and TAM receptor signaling sustains the integrity of the endothelial barrier, which restricts WNV transit.
The decrease in TEER in response to WNV infection in Axl −/− Mertk −/− BMECs might be due to an altered production of or response to cytokines (such as TNF-α) that independently affect the barrier. Indeed, we detected slightly increased levels (1.4-to 2.6-fold, P < 0.05) of TNF-α, IL-1β and IFN-γ during WNV infection of Axl −/− Mertk −/− BMECs (Fig. 4e,f and data not shown). Levels of other cytokines and chemokines (such as IL-2, IL-3, IL-6, IL-13, KC, MIP1-α and RANTES) were similar between WT and Axl −/− Mertk −/− BMECs (data not shown). Because TNF-α and IL-1β can disrupt BBB integrity 22 , we tested whether blockade of these cytokines in vitro during WNV infection might differentially alter barrier integrity. Treatment of BMECs with blocking antibodies against IL-1β and TNF-α before infection minimally increased TEER (1.1-to 1.2-fold, P < 0.05) in both WT and Axl −/− Mertk −/− BMECs, and this effect was evident only at late time points ( Fig. 4g) . Studies have suggested that TAM receptors can modulate the responsiveness of endothelial cells to TNF-α (ref. 22); therefore, we treated WT and Axl −/− Mertk −/− BMECs with soluble TNF-α, but we found no difference in TEER response ( Fig. 4h ; P > 0.9). npg Because Axl associates physically with Ifnar1 and modulates type I IFN signaling in DCs 11 , we hypothesized that TAM receptors might affect Ifnar signaling in BMECs, which could influence BBB tightening after WNV infection. To test this idea, we treated WT and Axl −/− Mertk −/− BMECs with IFN-β (Ifnar-dependent) or IFN-λ (Ifnar-independent) and measured TEER over 6 h. Whereas a deficiency of Axl and Mertk did not affect the ability of IFN-λ to increase TEER 22, 28 , Axl −/− Mertk −/− BMECs were less responsive to IFN-β treatment in terms of TEER changes (Fig. 4i) , although Ifnar1 expression was similar in WT and Axl −/− Mertk −/− BMECs (Supplementary Fig. 5d ). These results suggest that Axl and Mertk expression in BMECs is required for the full effect of IFN-β on barrier integrity. Colocalization of the tight junction (TJ) proteins claudin-5 and ZO-1 is enhanced by type I IFN during WNV infection 22 . We observed diminished claudin-5 expression at the cell membrane and discontinuities in TJs in Axl −/− Mertk −/− BMECs (Fig. 4j) We next tested the effects of Gas6 (ref. 4) (which binds to and activates both Axl and Mertk), either alone or in combination with IFN-β, on TEER in WT BMECs. We observed dose-dependent tightening of BMEC monolayers in response to Gas6 (Fig. 5a) . The combination of Gas6 and IFN-β rapidly tightened the barrier, with markedly increased TEER values observed within 15 min of treatment. Similar increases in TEER values were observed in a human BMEC line and with physiologic concentrations of Protein S, which functions as a ligand for Mertk and Tyro3 but not Axl 4 (Supplementary Fig. 6a,b) . Whereas Tyro3 −/− and Axl −/− BMECs responded to Gas6 similarly to WT cells (Fig. 5b,c) , Axl −/− BMECs exhibited decreased baseline TEER (Fig. 5c) . Consistent with its more dominant role in maintaining BBB integrity in vivo ( Figs. 2a and 3b) , signaling through Mertk was required for the increase in TEER in response to Gas6 (Fig. 5d) . A combined genetic deficiency of Axl −/− and Mertk −/− did not increase the barrier defect beyond that observed in Mertk −/− BMECs in response to Gas6 and IFN-β ( Fig. 5d,e) .
To further investigate the interaction between TAM receptors and type I IFN signaling, we treated Ifnar1 −/− BMECs with Gas6. Type I IFN signaling was not required for Gas6-dependent effects on TEER at 30 and 60 min after treatment, although an absence of Ifnar1 diminished the amplitude of the effect at all of the time points tested (Supplementary Fig. 7a ). We confirmed these findings with the Ifnar-blocking antibody MAR1-5A3 (ref. 29) , which was incubated with WT BMECs immediately before Gas6 addition (Supplementary Fig. 7b ). Thus, TAM receptor ligands activate Mertk to tighten the junctions of BMEC monolayers in a manner that cooperates with, but does not require, Ifnar1 signaling, and the effect of Mertk on endothelial barrier integrity is amplified when type I IFN signaling occurs concurrently.
We examined how Gas6-dependent TAM receptor signaling affected the activity of Rac1, a Rho family GTPase that regulates cytoskeletal dynamics, TJ integrity and paracellular permeability 30 . IFN-β enhances BMEC barrier formation in part by activating Rac1 (ref. 22) , and Mertk signaling promotes Rac1 activation in macrophages in the context of the phagocytosis of apoptotic debris 31 . We measured GTP-bound, activated Rac1 after treatment with IFN-β, Gas6 or IFN-β and Gas6. Notably, Gas6 treatment was sufficient to enhance Rac1 activation in BMECs, similarly to the effect observed with IFN-β alone ( Fig. 5f ; twofold, P < 0.005). The combination of Gas6 and IFN-β led to a further increase in Rac1 activation. Finally, blockade of Rac1 activation with the Rac1 inhibitor Z62954982
prevented Mertk-or IFN-β-dependent tightening of BMEC barriers (Fig. 5g) . Thus, cytoskeletal reorganization resulting from Gas6-induced activation of Rac1 is probably required to sustain TJ integrity and the endothelial barrier.
We evaluated Axl and Mertk expression in cells of the neurovascular unit by confocal microscopy (Supplementary Fig. 8a,b) . In addition to expression on endothelial cells (Supplementary Fig. 5a-c) , we observed costaining of TAM receptors in S100-β + astrocytes and CD11b + myeloid cells. To evaluate whether TAM receptor expression on astrocytes contributed to endothelial barrier integrity, we used the in vitro BBB model to test whether the TEER response to Gas6 stimulation was different between WT and Axl −/− Mertk −/− astrocytes and found that deletion of Axl and Mertk in astrocytes had no effect on TEER responses (Fig. 6a) .
The effect of Mertk expression on BBB permeability occurred both in vitro and in vivo, without appreciable effects on viral replication in peripheral organs or on CD8 + T cell responses. To confirm that the dominant effect on BBB permeability of Mertk occurred at the level of the neurovascular unit and not in peripheral immune cells, we generated Mertk bone marrow-chimeric mice. To prevent adventitious effects of radiation on the BBB, the heads of mice were shielded with npg lead (Fig. 6b) . Bone marrow chimeras with Mertk-deficient radioresistant nonhematopoietic cells (SJL→Mertk −/− ) exhibited the same BBB permeability defect on day 4 after WNV infection as Mertk −/− mice, whereas the reciprocal chimeras (Mertk −/− →SJL) with Mertksufficient nonhematopoietic cells did not (Fig. 6c) . A trend toward a parallel effect on viral burden was observed with 7 of 8 SJL→Mertk −/− mice having detectable WNV RNA in the brain at 4 d.p.i. as compared to 3 of 8 Mertk −/− →SJL mice ( Fig. 6d ; P = 0.06). These results are consistent with a model in which Mertk expression on radio-resistant cells within the CNS is required for maintenance of BBB integrity.
DISCUSSION
Many enveloped viruses bind to and activate TAM receptors to disable innate immune responses and enhance infection 19 . Because we previously observed slightly lower levels of WNV replication in Axl −/− Mertk −/− DCs 19 , we hypothesized that TAM receptor-deficient mice would be protected against lethal WNV infection. However, we show here that a genetic deficiency of Axl and Mertk resulted in the early appearance of WNV into the CNS that resulted in enhanced viral load and mortality. The increased mortality was associated with increased BBB permeability and revealed a dominant role for Mertk in maintaining the integrity of this key barrier during viral infection. Using an in vitro BBB model, we found that Mertk promoted endothelial barrier integrity by maintaining the co-localization of TJ proteins. Additionally, the barrier-tightening effect of Mertk signaling was cooperative with the response to IFN-β. Our discovery that Axl −/− and Mertk −/− mice were more vulnerable to neuroinvasive WNV and LACV infections suggests that although enveloped viruses can usurp TAM receptors, these proteins nonetheless can restrict the pathogenesis of some viruses that target the CNS. When WNV was introduced directly in the CNS by intracranial injection in TAM receptor-deficient mice, no increase in viral replication in different brain regions was observed. Thus, blockade or ablation of TAM receptors may have varying effects on viral pathogenesis, depending on the balance between virus binding to TAM receptors via Protein S and/or Gas6 and the resulting effects on the intracellular antiviral environment and/or vascular endothelial barrier integrity. Our data also demonstrate a separate role for Axl in modulating T cell immunity, which could affect viral clearance in different tissues, including the CNS.
Although we did not assay the level of infection in TAM-deficient DCs in vivo, peripheral viral burden was similar in WT, Axl −/− and Mertk −/− animals, suggesting that the earlier and greater viral burden in the CNS reflects accelerated virus entry owing to impaired BBB integrity, and that TAM receptor engagement by WNV is not required for infection in vivo. However, WNV infection was slightly greater in the blood and spleens of Axl −/− Mertk −/− mice than in WT animals, the mechanism of which requires further study. Studies of bone marrow chimeras revealed that the BBB permeability phenotype tracked with a loss of Mertk expression on radio-resistant, and not radio-sensitive, hematopoietic cells. Mertk + radio-resistant cells in the CNS also include microglia 32, 33 , which can express Axl upon activation; as such, we do not exclude the possibility that the enhanced lethality in WNV-infected Axl −/− mice might reflect a role for this TAM receptor in microglia.
Ifnar-dependent signaling was required for optimal endothelial cell barrier integrity after treatment with the TAM ligand Gas6. Studies in myeloid cells have shown that Axl associates with and signals through npg the Ifnar1 subunit 11 , and it is plausible that Mertk could function analogously in endothelial cells. Although biochemical corroboration is required, Mertk may modulate the barrier-tightening effects of IFN-β in endothelial cells because of a specific interaction with Ifnar1 (ref. 11) . The defects in the stabilization of endothelial TJs in Axl −/− Mertk −/− BMECs are consistent with TAM receptor-dependent regulation of cytoskeletal reorganization in other cell types, which occurs through Rac1 (refs. 31,34) . We observed Rac1 activation in response to Gas6 in endothelial cells, which was amplified with concurrent IFN-β treatment. Our results are consistent with a model in which TAM receptor (preferentially Mertk) and Ifnar signaling together activate Rac1, which leads to tightening of BMEC junctions and restriction of virus transit into the CNS (Fig. 6e) .
Axl −/− mice had impaired CD8 + T cell responses to WNV infection, which could impact mortality by affecting CNS viral clearance 35, 36 . We did not observe CD8 + T cell defects in peripheral or CNS tissues of Mertk −/− mice, suggesting distinct functions of Axl and Mertk in modulating adaptive immunity during viral infections. A diminished T cell response in Axl −/− mice is consistent with a prior study of HSV infection 21 . However, the attenuated CD8 + T cell response does not explain the early appearance of WNV in the brain at day 4 after infection in Axl −/− mice, as this time point precedes that of the induction of a WNV-specific CD8 + T cell response 37 .
Prior reports have suggested possible functions of TAM receptors in endothelial cells. Mice lacking all three TAM receptors (Axl −/− Mertk −/− Tyro3 −/− triple-knockout mice) reportedly have a disrupted BBB, although this was attributed in part to autoimmune disease 38 . Exogenous administration of Protein S enhanced BBB integrity after ischemic stroke, although this phenotype required Tyro3 and not Axl or Mertk 25 . Thus, individual TAM receptors may have unique roles in maintaining BBB integrity under different inflammatory conditions. Mertk may have a dominant function in maintaining the BBB after viral infection, whereas Tyro3, which also is expressed on neurons, may be more important in the context of cerebral ischemia. Protein S, which is a ligand for both Tyro3 and Mertk, is probably the relevant TAM ligand, as Protein S is abundant in serum in which Gas6 is present at lower levels 39 .
Our discovery that TAM signaling regulates BBB integrity in the context of viral infections has clinical implications, because TAM receptor antagonists are being developed as cancer therapies 40 . Mertk blockade could increase the risk of neuroinvasion and pathogenesis of certain viruses, including WNV and LACV. Indeed, in studies with a broad-spectrum inhibitor of TAM signaling 41 , we observed increased lethality in mice after WNV infection and increased BBB permeability. Further experiments are warranted to define the net effects of TAM receptor blockade in the context of infection by different families of visceral and encephalitic viruses.
METhODS
Methods and any associated references are available in the online version of the paper. 
ONLINE METhODS
Viruses and cells. The WNV strain (3000.0259) was isolated in New York in 2000 and passaged once in C6/36 Aedes albopictus cells. Mice were inoculated subcutaneously in the footpad with 100 plaque forming units (p.f.u.) of WNV diluted in Hanks balanced salt solution. Viral titers in tissues were analyzed by plaque assay using Vero cells, as described previously 36 . The LACV strain (original strain) was provided by A. Pekosz (Johns Hopkins University, Baltimore, Maryland, USA) and passaged twice in Vero cells to produce a virus stock.
Mice. C57BL/6J wild-type (WT) mice were commercially obtained from Jackson Laboratories. Axl −/− , Mertk −/− , Axl −/− Mertk −/− and Tyro3 −/− mice have been published 42 and were backcrossed for ten generations. All mice were housed in a pathogen-free mouse facility at the Washington University School of Medicine and experiments were performed in accordance with federal and university regulations. Measurement of viral burden. At specified time points after WNV and LACV infection, serum was obtained by intracardiac heart puncture, followed by intracardiac perfusion (20 ml of PBS) and organ recovery. Organs were weighed, homogenized using a bead-beater apparatus, and WNV was titrated by plaque assay on Vero cells 43 . Brains from LACV-or WNV-infected mice were harvested at day 8 after infection and the total RNA was extracted using the RNeasy kit (Qiagen). For LACV, viral load in the brain was determined by qRT-PCR. Briefly, all reactions were assembled in a final volume of 25 µl with 300 ng of RNA, 10 µM forward and reverse primers (LACV: Forward 5′-CCTTGCTGCAGTTAGGATCTTCTT-3′, Reverse 5′-CCACTCTCCAAATTTAGG-GTTAGC-3′; GAPDH: Forward 5′-AATGGTGAAGGTCGGTGTG-3′, Reverse: 5′-GTGGAGTCA TACTGGAACATGTAG-3′), 5 µM probe (LACV: 5′-5′-/56-FAM/ AGGCCA AGGCTGCTCTCTCGCGTA-/36-TAMSp/-3′; GAPDH: 5′-/56-FAM/TGCA AATGG/ZEN/CAGCCCTGGTG/3IABkFQ/-3′) and 12.5 µl of TaqMan master mix (Applied Biosystems) using the following cycling condition: 48 °C for 30 min and 95 °C for 10 min, followed by 45 cycles of 95 °C for 15 s and 60 °C for 1 min. Quantitation of WNV RNA was performed as previously described 44 . The levels of viral RNA were expressed on a log 10 scale as 'genome equivalents/gram after comparison with a standard curve produced using serial 10-fold dilutions of WNV or LACV RNA.
Quantification of type I IFN activity. Levels of type I IFN were determined using an encephalomyocarditis virus cytopathic effect bioassay performed in L929 cells as described previously 45 . Serum samples were treated with citrate buffer (40 mM citric acid, 10 mM KCl, 135 mM NaCl (pH 3.0)) for 10 min and neutralized with medium containing 45 mM HEPES pH 8.0. The amount of type I IFN per ml of serum was calculated from a standard curve using IFN-β (PBL Assay Science). The specificity of the antiviral activity was confirmed by pre-incubating L929 cells for 2 h with 25 µg/ml of the Ifnar-blocking monoclonal antibody (MAb) MAR1-5A3 or an isotype control, MAb GIR-208 (ref. 29) .
Cytokine bioplex assay. WT, Axl −/− , Mertk −/− and Axl −/− Mertk −/− mice were infected with WNV, and at specified times blood was collected and serum was prepared. The BioPlex Pro Assay was performed according to the manufacturer's protocol (BioRad). The cytokine screen included IL-1α, IL-1β, IL-2, IL-3 IL-4, IL-5, IL-6, IL-9, IL-10, IL-12p40, IL-12p70, IL-13, IL-17, eotaxin, G-CSF, GM-CSF, IFN-γ, KC, MCP-1, MIP-1α, MIP-1β, RANTES (CCL5) and TNF-α.
BBB permeability measurements.
Mice were infected with 100 p.f.u. of WNV or diluent (mock), and BBB permeability was assessed after 4 d. Sodium fluorescein (100 mg/ml) was administered via an intraperitoneal route in 100 µl. After 45 min, blood was collected by cardiac puncture into EDTA-coated tubes.
Mice were perfused and CNS tissues were harvested, homogenized into PBS, clarified by centrifugation, precipitated in 1% trichloroacetic acid and neutralized with borate buffer (Sigma-Aldrich). Fluorescence emission at 485 and 528 nm was determined using a microplate reader Synergy H1 and Gen5 software (BioTek Instruments, Inc.). Fluorescein concentration was calculated from a standard curve, and tissue fluorescence values were normalized to the plasma fluorescence values from the same mouse.
Endogenous mouse IgG was detected in brain sections using an AlexaFluor-488 anti-mouse IgG antibody (Becton Dickinson). Nuclei were stained with Topro-3 (ThermoFisher Scientific). Images were acquired with a laser-scanning confocal microscope (Zeiss LSM 510 META) and analyzed with LSM image browser software (Zeiss).
Drug treatment studies. The small molecule receptor inhibitor BMS-777607 (Selleckchem) was dissolved in DMSO at a stock concentration of 52 mg/ml. Mice received either 1 mg BMS-777607 dissolved in 50 µl DMSO or 50 µl DMSO vehicle control by oral gavage beginning 1 d before infection and continuing through day 4 after infection.
B cell and antibody responses. The levels of WNV-specific IgM and IgG were determined using an ELISA against purified WNV E protein, as described previously 46 . Plaque reduction neutralization assays on BHK21-15 cells were performed after mixing serial dilutions of serum with a fixed amount (100 p.f.u.) of WNV, as previously described 47 .
Cellular immune responses. WT and TAM receptor-deficient mice were inoculated in the footpad with 100 p.f.u. of WNV and at day 8 after infection, spleens and brains were harvested after extensive cardiac perfusion with PBS. Splenocytes were dispersed into single-cell suspensions with a cell strainer. Brains were digested collagenase, and leukocytes were isolated as previously described 48 . Intracellular IFN-γ or TNF-α staining was performed after ex vivo restimulation with a D b -restricted NS4B immunodominant peptide using 1 µM of peptide and 5 µg/ml of brefeldin A (Sigma) as described 49 . Cells were stained with the indicated antibodies to the following proteins and processed by multicolor flow cytometry on an LSR II flow cytometer (Becton Dickinson): CD3 (Becton Dickinson, clone 145-2C11), CD4 (Biolegend, clone RM4-5), CD8-β (Biolegend, clone YT5156.7.7), CD19 (Invitrogen, clone 6D5), CD45 (Biolegend, clone 30-F11), CD11b (Becton Dickinson, clone M1/70), IFN-γ (Becton Dickinson, clone XMG1.2) and TNF-α (Biolegend, clone MP6-XT22). Flow cytometry data were analyzed using FlowJo software (Treestar).
Transwell cultures and TEER measurements. WT and TAM receptor-deficient
BMECs and the human brain cerebral endothelial cell line HCMEC/D3 were grown in Transwell cultures until fully polarized 22 . BMECs were grown above astrocyte cultures, whereas HCMEC/D3s were grown without astrocytes. TEER was measured using a chopstick electrode with an EVOM voltmeter (World Precision Instruments). Resistance values are reported as 'Ω/cm 2 ' , with the resistance value for 'Transwell inserts with no cells' subtracted as background. TEER measurements were collected at 6 h following infection with WNV at an MOI of 0.01 or treatment with mouse IFN-λ3 (100 ng/ml), or mouse or human IFN-β (10 ng/ml) (PBL Assay Science); mock wells were treated with culture medium. To block IFN-α and IFN-β signaling, BMEC cultures were treated with 25 µg/ml of the blocking MAb MAR1-5A3 for one hour before infection. A nonbinding MAb (GIR-208) was used as an isotype control. To measure virus transit across the endothelial barrier, WNV was added to the upper chamber of the Transwell at an MOI of 0.01. After 6 h, virus in the lower chamber was measured by qRT-PCR. Recombinant full-length Gas6 was generated in HEK293 EBNA cells as previously described 4 . Human protein S was purchased from Haematologic Technologies (HCPS-0090).
Rac1 studies. Rac1 immunoprecipitation experiments were performed with an activated Rac1 agarose bead kit (Cell BioLabs, Inc.) according to the manufacturer's instructions. Purified, GTP-bound protein and unpurified BMEC protein lysates were separated via gel electrophoresis on 10% bis-Tris gels (Life Technologies) and transferred onto iBlot nitrocellulose transfer membranes (Life Technologies) according to standard protocols. To test the effects of Rac1 inhibition npg
